Europe PMC
Nothing Special   »   [go: up one dir, main page]

Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

IL28B rs12980275 variant as a predictor of sustained virologic response to pegylated-interferon and ribavirin in chronic hepatitis C patients: A systematic review and meta-analysis.

Author information

Affiliations

  • 1. Department of Ultrasonography, Hebei Chest Hospital, Shijiazhuang, 050041 Hebei Province, China.
      Authors
    • Zheng H 1
    (1 author)
  • 2. Department of Epidemiology and Biostatistics, School of Public Health, Hebei Medical University, Zhongshan East Road 361#, Shijiazhuang, 050017 Hebei Province, China.
      Authors
    • Li M 2
    • Chi B 2
    • Wu XX 2
    • Wang J 2
    • Liu DW 2
    (5 authors)

Clinics and Research in Hepatology and Gastroenterology, 10 Mar 2015, 39(5):576-583
https://doi.org/10.1016/j.clinre.2015.01.009 PMID: 25769643 

Review

Abstract 

Background and objective

The IL-28B rs12979860 CC and rs8099917 TT genotypes were proved to be predictor for pegylated-interferon (PEG-IFN)/ribavirin (RBV)-treated hepatitis C virus (HCV) patients. However, there were no identical conclusions on rs12980275 polymorphism. Our aim is to perform a meta-analysis in order to determine the association between rs12980275 polymorphism of IL28B and the sustain viral response (SVR) of HCV patients with PEG-IFN/RBV therapy.

Methods

Studies were retrieved from PubMed and Chinese China National Knowledge Infrastructure (CNKI). Data were extracted by two investigators and analyzed using Stata 11.0 software.

Results

Sixteen articles, containing 19 independent studies were included in the analysis. The results showed that patients with AA genotype of rs12980275 achieved higher SVR than patients with AG/GG genotypes. The overall OR (95% CI) was 3.118 (2.146, 4.529). In subgroup analysis by ethnicity, the ORs (95% CIs) were 3.084 (1.454, 6.542) and 2.736 (1.863, 4.018) in Asian and Caucasian population, respectively. Another subgroup analysis by HCV genotype, the ORs (95% CIs) were 3.976 (2.568, 6.158), 1.462 (0.504, 4.240) and 1.489 (0.916, 2.421) in patients with HCV genotype 1/4, mix genotype, and HCV genotype 2/3, respectively.

Conclusion

AA genotype of rs12980275 was a predictive factor for SVR in HCV patients with PEG-IFN/RBV treatment, especially in HCV genotype 1/4.

Full text links 

Read article at publisher's site: https://doi.org/10.1016/j.clinre.2015.01.009

References 

Articles referenced by this article (37)

Show 10 more references (10 of 37)

Citations & impact 

Impact metrics

9
Citations
Jump to Citations
4
Data citations
Jump to Data

Citations of article over time

Article citations

Go to all (9) article citations

Data 

Data behind the article

This data has been text mined from the article, or deposited into data resources.

SNPs

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.